title: Cerebral Amyloid Angiopathy-Related Inflammation Biomarkers: Where are we Now?
abstract: Cerebral amyloid angiopathy- related inflammation (CAA-ri) is an aggressive disease subtype of CAA with characteristic clinical and radiological findings. CAA-ri is an important diagnosis to reach in clinical practice, as patients typically respond to prompt immunosuppressive treatment. A definitive diagnosis of CAA-ri still requires a brain biopsy, and hence developing non-invasive diagnostic criteria and biomarkers for this syndrome are key priorities in the field. CAA-ri has gained additional interest for its notable similarities to amyloid-related imaging abnormalities, a complication of immunotherapy treatments in Alzheimer's disease patients. In this commentary, the current state of biomarkers research for CAA-ri and recently suggested diagnostic criteria are put into context.
authors.forename: Andreas
authors.initials: A
authors.lastname: Charidimou
mesh_terms: D015415:Biomarkers / Q000378:metabolism*; D016657:Cerebral Amyloid Angiopathy / Q000150:complications / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000378:metabolism*
chemical_list: D015415:Biomarkers
keywords: Alzheimer’s disease; amyloid-related imaging abnormalities (ARIA); cerebral amyloid angiopathy; cerebral microbleeds; cerebrospinal fluid biomarker